{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:46:03Z","timestamp":1782708363910,"version":"3.54.5"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Limited research is currently available regarding the prognostic value of Fc receptor-like 5 (FCRL5) in newly diagnosed multiple myeloma (NDMM). This study aimed to investigate the association of FCRL5 expression with treatment response and survival outcomes in NDMM patients, with a goal of providing insights for early risk stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed a cohort comprising 54 NDMM patients treated between January 2024 and January 2025 at a single center. Pretreatment FCRL5 expression was quantified by flow cytometry, and the median value (75.15%) was utilized to stratify patients into two groups: high expression group and low expression group for comparison of baseline characteristics, treatment response, and survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline characteristics, including age and disease stage, were balanced between the two FCRL5 expression groups, with all\n                      <jats:italic>P<\/jats:italic>\n                      -values &amp;gt; 0.05. After four induction cycles, the group with high FCRL5 expression showed substantially lower rates of complete response (25.93% vs. 51.85%), \u2265very good partial response (33.33% vs. 70.37%), and minimal residual disease negativity (29.63% vs. 70.37%) (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.05 for all). At 10.3-month median follow-up, the median progression-free survival (PFS) (10.6 months in contrast to not reached,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.002) and overall survival (OS) (13.2 months as opposed to not reached,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.02), as well as 1-year PFS rate (21.43% vs. 76.47%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.004) were markedly shorter. Multivariate regression analysis confirmed high FCRL5 expression as an independent adverse prognostic factor for both PFS (\n                      <jats:italic>HR<\/jats:italic>\n                      7.32, 95%\n                      <jats:italic>CI<\/jats:italic>\n                      1.86 - 28.74,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.004) and OS (\n                      <jats:italic>HR<\/jats:italic>\n                      9.82, 95%\n                      <jats:italic>CI<\/jats:italic>\n                      1.01 - 95.10,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.049).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High FCRL5 expression was significantly associated with inferior response depth and survival in NDMM. Our findings suggested that FCRL5 may serve as a valuable biomarker for risk stratification, though further prospective validation is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1765006","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:26:41Z","timestamp":1782707201000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["High FCRL5 expression predicts poor treatment response and survival in newly diagnosed multiple myeloma: a retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Cainan","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengtian","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyue","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiling","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingshan","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunming","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01513","article-title":"Prevalence and incidence of multiple myeloma in urban area in China: A national population-based analysis","volume":"9","author":"Wang","year":"2019","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800170008","article-title":"Multiple myeloma","volume":"24","author":"H\u00e1jek","year":"2011","journal-title":"Klin Onkol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20231113-01078","article-title":"Current status and challenges of immunotherapy for multiple myeloma (In Chinese)","volume":"104","author":"Lu","year":"2024","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05730-y","article-title":"Therapeutic progress in relapsed\/refractory multiple myeloma","volume":"103","author":"Chen","year":"2024","journal-title":"Ann Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.25259\/Cytojournal_64_2023","article-title":"Exploring the efficacy and safety of anti-BCMA chimeric antigen receptor T-cell therapy for multiple myeloma: Systematic review and meta-analysis","volume":"21","author":"Zhang","year":"2024","journal-title":"Cytojournal"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3321\/j.issn:0254-5101.2008.09.022","article-title":"Research progress on the FcRL gene family (In Chinese)","volume":"28","author":"Sang","year":"2008","journal-title":"Chin J Microbiol Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1189\/jlb.0211096","article-title":"Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes","volume":"91","author":"Dement-Brown","year":"2012","journal-title":"J Leukoc Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215156110","article-title":"FCRL5 exerts binary and compartment-specific influence on innate-like B-cell receptor signaling","volume":"110","author":"Zhu","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxl069","article-title":"Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia","volume":"18","author":"Polson","year":"2006","journal-title":"Int Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014982","article-title":"Anti-FcRL5 CAR-T exhibits anti-MM activity against EMM after progression of anti-BCMA and anti-GPRC5D CAR-T: a case report","volume":"9","author":"He","year":"2025","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxae028","article-title":"Humoral responses are enhanced by facilitating B cell viability by Fcrl5 overexpression in B cells","volume":"36","author":"Ono","year":"2024","journal-title":"Int Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41392-023-01702-2","article-title":"Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma","volume":"9","author":"Yu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1038\/s41467-023-39395-4","article-title":"Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0178-8","article-title":"Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma","volume":"9","author":"Stewart","year":"2019","journal-title":"Blood Cancer J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23751","article-title":"Fc receptor-like 1-5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia","volume":"123","author":"Kazemi","year":"2008","journal-title":"Int J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-4992.2022.02.027","article-title":"Clinical analysis of clinical characteristics, relationship between FISH test results and efficacy in patients with multiple myeloma (In Chinese)","volume":"30","author":"Guo","year":"2022","journal-title":"Modern Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn121090-20240430-00167","article-title":"Chinese expert consensus on minimal residual disease detection in multiple myeloma based on bone marrow samples (2024) (In Chinese)","volume":"45","year":"2024","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique Malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.2097-0005.2025.05.001","article-title":"Efficacy and prognostic factors of novel drugs in the treatment of multiple myeloma (In Chinese)","volume":"46","author":"Li","year":"2025","journal-title":"J Shandong First Med Univ Shandong Acad Med Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1673-4130.2025.17.018","article-title":"Research progress on biomarkers related to the diagnosis and prognosis of multiple myeloma (In Chinese)","volume":"46","author":"Qi","year":"2025","journal-title":"Int J Lab Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202860","article-title":"Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors","volume":"190","author":"Franco","year":"2013","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.973836","article-title":"Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche","volume":"12","author":"Solimando","year":"2022","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1182\/blood-2023-177669","article-title":"Co-expression of GPRC5D, FcRH5 and BCMA suggests that targeting more than one cell surface marker may be a viable strategy in relapsed\/refractory multiple myeloma (RRMM): Biomarker results from the phase I study of Forimtamig, a GPRC5DxCD3 bispecific antibody","volume":"142","author":"Dekhtiarenko","year":"2023","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.938392","article-title":"The independent adverse prognostic significance of 1q21 gain\/amplification in newly diagnosed multiple myeloma patients","volume":"12","author":"You","year":"2022","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.631134","article-title":"Variants of novel immunomodulatory Fc receptor like 5 gene are associated with multiple sclerosis susceptibility in the Polish population","volume":"12","author":"Chorazy","year":"2021","journal-title":"Front Neurol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-4761.2025.02.015","article-title":"The expression of FOXF1 and FCRL5 in hepatocellular carcinoma tissue and their relationship with clinical pathological fea tures and prognosis (In Chinese)","volume":"33","author":"Zhou","year":"2025","journal-title":"J Hepatobiliary Surg"},{"key":"B32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12859-022-04657-3","article-title":"Bioinformatics analysis reveals immune prognostic markers for overall survival of colorectal cancer patients: A novel machine learning survival predictive system","volume":"23","author":"Zhang","year":"2022","journal-title":"BMC Bioinf"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1381212","article-title":"Circulating immune cells and risk of osteosarcoma: A Mendelian randomization analysis","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.174","article-title":"Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma","volume":"22","author":"Breitkreutz","year":"2008","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","article-title":"Proteasome inhibition in multiple myeloma: Head-to-head comparison of currently available proteasome inhibitors","volume":"26","author":"Besse","year":"2019","journal-title":"Cell Chem Biol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41571-024-00913-y","article-title":"Just scratching the surface: Novel treatment approaches for multiple myeloma targeting cell membrane proteins","volume":"21","author":"Neri","year":"2024","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1765006\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:26:47Z","timestamp":1782707207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1765006\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":36,"alternative-id":["10.3389\/fonc.2026.1765006"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1765006","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"article-number":"1765006"}}